Summit Therapeutics Share Discussion Threads

[chrisatrdg] 06/12/2018 12:33

Totally agree with waterloo01 - Cash is king & equally important that Summit are still sticking to Qtr 1 2019 for C-Diff - if I had the funds I would be doubling my current 50,000 share holding.

[solomon] 06/12/2018 12:22

football - what's a 'now koffing' (24511)?

[waterloo01] 06/12/2018 12:15

We'll see but when it's trading so far below cash.....

[football] 06/12/2018 12:10

Waterloo knowing our directors the only thing they be buying is Christmas presents out of their options from the company

[football] 06/12/2018 12:05

Dam got three lots next week so it even can have a a very good Christmas or the final now Koffing

[football] 06/12/2018 12:03

Summit Therapeutics plc
(‘Summit’ or the ’Company’)

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018

Oxford, UK, and Cambridge, MA, US, 6 December 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the third quarter and nine months ended 31 October 2018 on 11 December 2018.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics to treat infections caused by C. difficile, N. gonorrhoea and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

[algernon2] 05/12/2018 17:19

Not Glyns fault the DMD drug failed. We all share the pain.

[lagosboy] 05/12/2018 09:19

I would be happy with a cash or all share deal - at least they might go somewhere.

Problem is the acquisition price is just the start- to get these drugs to market costs hundreds of millions and after all this time I can't see that being likely.

The recent focus on a STI is a sign that Summ is on the way out, not up.

I getting close to writing this one off altogether. Well done Glyn.

[multiplural] 05/12/2018 09:10

As a shareholder I think we should put this company up for sale. I would be surprised if we couldn't get some 75p per share for it.

[football] 05/12/2018 08:46

Perhaps we could go into the energy sector with all Glyn's hot air as it would solve global warming being a natural resource which is renewable on a daily basis

[lagosboy] 05/12/2018 08:39

Summit seems to have the cure for everything except producing shareholder value.

Oh well, at least Glyn's got some new conferences to frequent in 2019.

[chrisatrdg] 04/12/2018 21:55

Neisseria gonorrhoeae — Rising Infection Rates, Dwindling Treatment Options (08/11/18)

[waterloo01] 03/12/2018 15:23

Until the results the directors are in a closed period. One hopes to see that change once out.

[lagosboy] 30/11/2018 17:57

Waterloo- they are neither a new or existing II taking a current interest at these levels, they are merely disclosing that they failed to aggregate their US & UK holdings back in March 2018 as they should have done for disclosure purposes.

I suspect they have become aware of this having reviewed their position in Summ which must be well under water.

Fingers crossed for next week, but we have been saying that for years.

[waterloo01] 30/11/2018 13:43

Good to see a new II taking an interest at this level. Edit: they actually crossed this level in March and are only now reporting it!

[chrisatrdg] 30/11/2018 12:51

Hi markth126 - This share is not doomed & will recover & expect to be at £1 sometime next year although the % increase required to achieve that is getting bigger by the day.

[markth126] 30/11/2018 07:28

Is this doomed or will there ever be any recovery , holding since £2 days

[waterloo01] 29/11/2018 16:09

Tweeted by anti-microbial s

[chrisatrdg] 28/11/2018 17:03

NASDAQ was looking good this evening now currently $1.28 = £0.20 down on earlier share price Lets hope we have positive results for Qtr 3 all being well next week.

PS I agree with waterloo01 sentiments.

[lagosboy] 27/11/2018 17:59

Hopefully Waterloo but I am now very circumspect when it comes to Glyn - the way he lead investors up the garden path at Antisoma was dreadful and he has a reputation within the industry of looking after himself very well.

Rdz is a perfectly good drug and he had some golden windows of opportunity in the past to transform the business but not sure he could accept the loss of the personal control that would accompany bringing in third party funding or partnerships.

We can only hope but it is not looking good by any measure at the moment.

[waterloo01] 27/11/2018 17:29

I agree it's been too long, but suspect the greatest part of that was the focus on DMD. Once that failed and was stopped, it should be all go on Rdz. Hopefully 3rd Q numbers will enlighten.

[lagosboy] 27/11/2018 17:12

We only have a very limited P2 proof of concept trial in CDI patients and Ridinilazole was expected to enter P3 clinical studies I the first half of 2018, we are nearing the end of 2018 so a company y update is needed but clearly the market is expecting any good news.

Whilst Europharma is a substantial pharma with operations throughout Latin America, is has not really any significant financial commitment to licensing Ridinilazole - its a one way deal which is normal as licensees arte te holy grail for small pharma's.